Anne Elise Herold Li
Overview
When biotech innovations and licenses lead to conflict—or companies need advice avoiding it—companies trust Anne Li for outside-the-box strategies. She represents clients whose groundbreaking products and services raise complex legal questions at the nexus of competitors and collaborators, including those times when one shifts to the other. She has significant experience in the biotech, pharma, life sciences, and medical device sectors, handling high-stakes litigation in patent, trade secret, and licensing disputes.
Career & Education
- University of Chicago, B.A., psychology
- Emory University, M.P.H.
- Fordham University School of Law, J.D.
- District of Columbia
- New York
- Supreme Court of the United States
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the District of Columbia
- U.S. Patent and Trademark Office (USPTO)
Professional Activities and Memberships
- Vice-Chair, Medical Devices, ABA Science & Technology Law Section, 2017 – 2018
- New York Intellectual Property Law Association
- Executive Committee, William C. Conner Inn of Court
Anne's Insights
Client Alert | 3 min read | 07.16.24
The USPTO has proposed a rule rendering a patent unenforceable if it is disclaimed over another patent that is subsequently found invalid. The FTC filed a comment letter in support of the USPTO’s proposed rule, noting that “the proposed rule would reduce the costs incurred by potential competitors challenging weak patents or defending against assertions of patent claims that are obvious variants of a single invention.”
Client Alert | 4 min read | 06.26.24
Firm News | 9 min read | 06.06.24
Firm News | 2 min read | 06.06.24
Representative Matters
- Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
- Successfully defended Agilent against a preliminary injunction filed by Waters Corp. by demonstrating that Waters was unlikely to succeed on the merits. The case ultimately settled.
- Successfully represented a large pharmaceutical company in a false advertising and unfair competition case.
Anne's Insights
Client Alert | 3 min read | 07.16.24
The USPTO has proposed a rule rendering a patent unenforceable if it is disclaimed over another patent that is subsequently found invalid. The FTC filed a comment letter in support of the USPTO’s proposed rule, noting that “the proposed rule would reduce the costs incurred by potential competitors challenging weak patents or defending against assertions of patent claims that are obvious variants of a single invention.”
Client Alert | 4 min read | 06.26.24
Firm News | 9 min read | 06.06.24
Firm News | 2 min read | 06.06.24
Recognition
- The National Law Journal: Emerging Therapies/Life Sciences Trailblazer, 2023
- IAM Patent 1000: Recommended – United States: National, Trade Secret Litigation, 2023
- Law360: Burton Award, Distinguished Legal Writing, 2023
- Chambers USA: Intellectual Property: Patent (Up and Coming) – New York, 2022-2023
Anne's Insights
Client Alert | 3 min read | 07.16.24
The USPTO has proposed a rule rendering a patent unenforceable if it is disclaimed over another patent that is subsequently found invalid. The FTC filed a comment letter in support of the USPTO’s proposed rule, noting that “the proposed rule would reduce the costs incurred by potential competitors challenging weak patents or defending against assertions of patent claims that are obvious variants of a single invention.”
Client Alert | 4 min read | 06.26.24
Firm News | 9 min read | 06.06.24
Firm News | 2 min read | 06.06.24
Practices
- Intellectual Property Litigation
- IP Prosecution and Portfolio Management
- Trade Secrets
- Litigation and Trial
- Trademark Counseling and Litigation
- Patent Litigation
- E-Discovery and Information Management
- U.S. ITC Section 337
- Post-Grant Proceedings
- False Advertising Disputes and Litigation
- Intellectual Property
- Copyright Counseling and Litigation
- Health Care
- Digital Health and Health Information Technology
Anne's Insights
Client Alert | 3 min read | 07.16.24
The USPTO has proposed a rule rendering a patent unenforceable if it is disclaimed over another patent that is subsequently found invalid. The FTC filed a comment letter in support of the USPTO’s proposed rule, noting that “the proposed rule would reduce the costs incurred by potential competitors challenging weak patents or defending against assertions of patent claims that are obvious variants of a single invention.”
Client Alert | 4 min read | 06.26.24
Firm News | 9 min read | 06.06.24
Firm News | 2 min read | 06.06.24